IRCT20220211053992N8Not yet recruitingUnknown
In vivo bioequivalence study of Sofosbuvir/Daclatasvir (400/60) manufactured by Bakhtar Bioshimi Co. compared with innovator product
Conditions
Trial Snapshot
- Phase
- Unknown
- Status
- Not yet recruiting
- Enrollment
- 24
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 59 years (—)
- Sex
- Male
Inclusion Criteria
- •General Health (in terms of Liver, Heart and Kidney)
Exclusion Criteria
- •History of cardiovascular disease, liver and kidney disease
- •Alcohol and drug addiction
- •History of drug allergy
Investigators
Similar Trials
Recruiting
Not Applicable
In-vivo Bioequivalence Test of Daclaasvir/Sofosbuvir 60/400 mg Actero Middle East with brand drug (Sofosbovir/Daclatasivir® 400/60 mg, Mylan, Germany)IRCT20200105046010N68Actero middle east Pharm Co.24
Completed
Phase 2
Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19COVID-19.2019-nCOV diseaseU07.1IRCT20200324046850N2Abadan University of Medical Sciences62
Completed
Phase 3
Evaluation of the effect of sofosbuvir/daclatasvir in COVID-19 patientsCOVID-19.U07.1COVID-19IRCT20200624047908N1Abadan University of Medical Sciences1,000
Completed
Not Applicable
Sofosbuvir and Daclatasvir for treatment of Hepatitis-C in patients undergoing hemodialysis.IRCT20170614034526N3Jinnah Hospital, Lahore36
Active, not recruiting
Phase 1
Epclusa blood concentrations after crushing the tablet compared to the whole tablet.hepatitis C virusMedDRA version: 20.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-003941-27-NLRadboud University Medical Center1